BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

BioNTech SENASDAQ: BNTX

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents falls 5.2% from a year ago

Cash & equivalents stood at €9.74B at the end of Q2 FY2026, down 5.2% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at -17.9% a year.

Context

  • Cash & equivalents amounted to 47.9% of total assets at the end of Q2 FY2026, up 0.4 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -5.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€9.74B-2.1% QoQ
Last fiscal yearDec 2025
€7.67B-21.4% YoY
Year agoJun 2025
€10.27B-5.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.2%——
1 year-21.4%——
3-year CAGR-17.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

EUR · from the balance sheet

Latest · FY2025
7.67B EUR
Year-over-year change
-21.4%
4-year CAGR
+45.9%

Cash & Equivalents vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -5.2% is the 7th highest of 11, against a peer median of -2.3%.
  • Cash & equivalents amounts to 47.9% of total assets for BNTX, versus a peer median of 19.5%.
BNTX Competitors
Cash & Equivalents for BNTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€9.74B EUR-5.2%-17.9%47.9%
INCYIncyte CorporationJun 2026$3.98B USD+103.7%+1.6%50.6%
GMABGenmab A/SJun 2026$1.5B USD+16.0%-44.3%12.0%
IMCRImmunocore Holdings plcMar 2026$452.68M USD-5.1%+5.1%42.2%
TGTXTG Therapeutics, Inc.Sep 2026$429.38M USD+479.6%-8.2%27.0%
IMTXImmatics N.V.Mar 2026€301.65M EUR+24.2%+32.5%55.5%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
IOVAIovance Biotherapeutics, Inc.Sep 2026$57.93M USD-63.4%-11.1%5.8%
IBRXImmunityBio, Inc.Sep 2026$45.08M USD-25.2%-5.5%7.4%
XNCRXencor, Inc.Jun 2026$44.66M USD+0.5%+0.1%6.2%
CGENCompugen Ltd.Mar 2026$12.44M USD-14.7%+101.6%8.5%
Peer median (excluding BNTX) —-2.3%-2.7%19.5%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.69B13.88B11.66B9.76B7.67B
Short-term Investments381.6M189.4M4.89B7.02B7.16B
Net Receivables12.38B7.15B2.34B1.52B984.48M
Inventory502.5M439.6M357.7M283.3M110.65M
Other Current Assets113.4M271.9M280.9M212.7M210.71M
Total Current Assets15.07B21.92B19.53B18.8B16.14B
Property, Plant & Equipment (Net)520.4M821.1M971.6M1.18B1.29B
Goodwill57.8M61.2M362.5M380.6M367.74M
Intangible Assets144.6M158.5M804.1M790.4M1.61B
Long-term Investments21.3M80.2M1.18B1.25B2.49B
Tax Assets0229.6M81.3M81.7M13.49M
Other Non-current Assets14.4M6.5M83.4M36.1M76.97M
Total Non-current Assets758.5M1.36B3.48B3.73B5.84B
Total Assets15.83B23.28B23.01B22.53B21.98B
Account Payables160M204.1M354M426.7M534.67M
Short-term Debt129.9M36M28.1M39.5M52.18M
Tax Payables1.57B595.9M525.5M4.5M0
Deferred Revenue186.1M77.1M353.3M294.9M754.58M
Other Current Liabilities1.44B2.04B809.6M1.76B734.39M
Total Current Liabilities3.48B2.95B2.07B2.52B2.14B
Long-term Debt171.6M176.2M191M214.7M29.89M
Deferred Tax Liabilities66.7M6.2M39.7M42.4M84.26M
Deferred Revenue (Non-current)9M48.4M398.5M183M87.96M
Other Non-current Liabilities208.2M42.1M60.7M155.3M234.5M
Total Non-current Liabilities455.5M272.9M689.9M595.4M621.84M
Total Liabilities3.94B3.22B2.76B3.12B2.76B
Common Stock246.3M248.6M248.6M248.6M258.89M
Retained Earnings9.88B18.83B19.76B19.1B17.95B
Accumulated OCI93.9M(848.9M)(984.6M)(1.33B)(1.46B)
Other Stockholders Equity00000
Minority Interest00000
Total Equity11.89B20.06B20.25B19.41B19.22B
Total Debt301.5M212.2M219.1M254.2M267.29M
Net Debt(1.39B)(13.66B)(11.44B)(9.51B)(7.4B)

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.